{"filing":{"accession_number":"0001193125-26-266040","cik":"0001681087","ticker":"TECX","company_name":"Tectonic Therapeutic, Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"d124600d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1681087/000119312526266040/d124600d8k.htm"},"events":[{"id":5683,"run_id":4978,"accession_number":"0001193125-26-266040","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Tectonic Therapeutic held its 2026 Annual Meeting of Shareholders on June 8, 2026, with voting results disclosed on three proposals: election of Class II directors Timothy A. Springer and Stefan Vitorovic, ratification of Deloitte \u0026 Touche LLP as independent auditor, and advisory approval of executive compensation. All three proposals passed with substantial majorities.","company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5983,"accession_number":"0001193125-26-266040","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from the 2026 Annual Meeting held on June 8, 2026. The filing reports voting outcomes on three proposals: election of Class II directors (Timothy A. Springer and Stefan Vitorovic), ratification of Deloitte \u0026 Touche LLP as independent auditor, and advisory approval of executive compensation. All three proposals passed with substantial majorities, and the disclosure includes detailed vote tallies (for, against, abstentions, and broker non-votes) as required by Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T21:10:09.053343+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":5684,"run_id":4978,"accession_number":"0001193125-26-266040","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The company announced completion of enrollment in the Phase 2 TX45 APEX clinical trial for a therapeutic candidate targeting pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). This represents a significant clinical development milestone for the company's pipeline.","company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5984,"accession_number":"0001193125-26-266040","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces completion of enrollment in a Phase 2 clinical trial (TX45 APEX) for a therapeutic candidate in pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). This is a material clinical development milestone for a biopharmaceutical company, but does not fit neatly into the standard taxonomy categories. While it is not an earnings release, M\u0026A activity, executive change, or financial restatement, the completion of Phase 2 enrollment represents a significant clinical and operational milestone that would affect a reasonable investor's assessment of the company's pipeline progress and development timeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T21:10:09.053343+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5983,"accession_number":"0001193125-26-266040","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from the 2026 Annual Meeting held on June 8, 2026. The filing reports voting outcomes on three proposals: election of Class II directors (Timothy A. Springer and Stefan Vitorovic), ratification of Deloitte \u0026 Touche LLP as independent auditor, and advisory approval of executive compensation. All three proposals passed with substantial majorities, and the disclosure includes detailed vote tallies (for, against, abstentions, and broker non-votes) as required by Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T21:10:09.053343+00:00","company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","filing_date":"2026-06-10"},{"id":5984,"accession_number":"0001193125-26-266040","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces completion of enrollment in a Phase 2 clinical trial (TX45 APEX) for a therapeutic candidate in pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). This is a material clinical development milestone for a biopharmaceutical company, but does not fit neatly into the standard taxonomy categories. While it is not an earnings release, M\u0026A activity, executive change, or financial restatement, the completion of Phase 2 enrollment represents a significant clinical and operational milestone that would affect a reasonable investor's assessment of the company's pipeline progress and development timeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T21:10:09.053343+00:00","company_name":"Tectonic Therapeutic, Inc.","ticker":"TECX","filing_date":"2026-06-10"}]}